Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics.
Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the
most important part of management. Available ocular management options include intravitreal antivascular
endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar),
vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical
practice with good clinical response and are currently the preferred mode of treatment worldwide.
Keywords: Aflibercept, aspirin, bevacizumab, diabetic retinopathy, glitazones, iluvien, i-vation, mecamylamine, medidur, midostaurin,
nepafenac, ozurdex, PASCAL, ranibizumab, retisert, ruboxistaurin, selective retina therapy (SRT), sorbinil, subthreshold
micropulse diode laser photocoagulation, VEGF.
Rights & PermissionsPrintExport